PRO-VAC DHPPL

Important safety and use flags

• Evidence boundary: exact strains, routes and schedule are traceable, but no public exact potency, onset, duration, challenge, field-outcome or internationally recognised regulator SPC was located.
• Primary schedule is 1 ml IM or SC at 8-9 and 12-14 weeks, adjusted for maternal antibody. Current core guidance requires a final CDV/CAV/CPV dose at >=16 weeks, sometimes later in high-risk settings; add or retime rather than assuming completion at 14 weeks.
• Complete scope: CPiV is non-core and this product cannot prevent every infectious respiratory syndrome. Its Canicola/Icterohaemorrhagiae Leptospira fraction does not establish Australis, Grippotyphosa, Pomona or universal strain coverage.
• The manufacturer calls the viral fraction live attenuated. A distributor page inconsistently calls several strains inactivated and expresses them as percentages; do not use those percentages as validated potency or silently resolve the conflict.
• A complete exact-product safety label was not found. Adverse-event frequency, contraindications, pregnancy/lactation, overdose, interactions and post-market safety are insufficient; this uncertainty is a clinical limitation, not proof of toxicity.
• Vaccinate only a clinically healthy dog after individual assessment. Defer and investigate fever, material illness, immunosuppression, pregnancy uncertainty or prior vaccine reaction; keep immediate hypersensitivity/anaphylaxis treatment available.
• Do not promise safety with another vaccine or medicine and do not mix beyond the supplied paired components unless the physical exact leaflet explicitly authorises it. Document every concomitant product and timing.
• Reconstitute the complete lyophilisate aseptically with its liquid Leptospira vial and give one full 1 ml dose by the selected IM or SC route. Do not divide by body weight or transfer an alternate product schedule.
• Maintain 2-8 C refrigerated, dark storage and verify the exact lot, expiry, vial integrity and physical leaflet. Public exact freeze tolerance and in-use time were not located; use promptly after reconstitution and discard uncertain material.
• Record exact product, batch, route, date, component-specific next due date and any reaction. Annual boosting is the manufacturer schedule; reassess local components and current evidence rather than assuming lifelong or broader protection.